title: [A meta-analysis on the safety of combination therapy with fenofibrate and statins].
abstract: OBJECTIVE
  The aim of this study was to assess the safety of fenofibrate-statin combination therapy.
  
  
  METHODS
  Medline, Cochrane Library, Web of Knowledge and CNKI were searched for 2184 randomized controlled trials. Finally, twenty-six studies with a total of 9494 participants were included in this analysis.
  
  
  RESULTS
  Compared with statins group, the fenofibrate-statin group had significantly higher incidence of aminotransferase elevations (OR 1.67, 95%CI 1.22-2.30, P < 0.05) . The two groups had identical incidence of creatin kinase elevations (OR 0.86, 95%CI 0.62-1.20, P > 0.05) , muscle-associated adverse events (OR 0.98, 95%CI 0.88-1.09, P > 0.05) and withdrawals due to hepatotoxicity or muscle toxicity. The safety of fenofibrate + standard-dose statin regimens were similar to those in fenofibrate-statin group.
  
  
  CONCLUSIONS
  Combined fenofibrate-statin treatment is generally safe and well tolerated, liver function should be monitored before and during and after therapy.
authors: Department of Cardiology, Peking University People's Hospital, Beijing 100044, China.
authors: Qiang
authors: Q
authors: Geng
authors: Department of Cardiology, Peking University People's Hospital, Beijing 100044, China.
authors: Jing-yi
authors: JY
authors: Ren
authors: Department of Cardiology, Peking University People's Hospital, Beijing 100044, China.
authors: Su-fang
authors: SF
authors: Li
authors: Department of Cardiology, Peking University People's Hospital, Beijing 100044, China. Email: chenhongbj@medmail.com.cn.
authors: Hong
authors: H
authors: Chen
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003131:Combined Modality Therapy; D011345:Fenofibrate / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D016032:Randomized Controlled Trials as Topic
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D011345:Fenofibrate